首页> 外国专利> RIG-Like Helicase Innate Immunity Inhibits VEGF-Induced Tissue Responses

RIG-Like Helicase Innate Immunity Inhibits VEGF-Induced Tissue Responses

机译:RIG类解旋酶先天性免疫抑制VEGF诱导的组织反应

摘要

The present invention encompasses compositions and compounds as well as methods of their use for the regulation of a VEGF-induced tissue response. A VEGF-induced tissue response may include angiogenesis, inflammation, increased vascular permeability, increased vascular leak, hemorrhage, or mucus metaplasia. As such, the present invention encompasses methods of treating diseases where a VEGF-induced tissue response is part of the disease's clinical presentation. Specifically, the present invention provides compounds and compositions as well as methods for treating acute lung injury (ALI), acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), obstructive sleep apnea (OSA), idiopathic pulmonary fibrosis (IPF), tuberculosis, pulmonary hypertension, pleural effusion, and lung cancer.
机译:本发明包括用于调节VEGF诱导的组织反应的组合物和化合物及其使用方法。 VEGF诱导的组织反应可能包括血管生成,炎症,血管通透性增加,血管渗漏增加,出血或粘液化生。这样,本发明包括治疗疾病的方法,其中VEGF诱导的组织应答是疾病临床表现的一部分。具体而言,本发明提供了用于治疗急性肺损伤(ALI),急性呼吸窘迫综合征(ARDS),哮喘,慢性阻塞性肺疾病(COPD),阻塞性睡眠呼吸暂停(OSA),特发性肺纤维化的化合物和组合物以及方法(IPF),肺结核,肺动脉高压,胸腔积液和肺癌。

著录项

  • 公开/公告号US2011245323A1

    专利类型

  • 公开/公告日2011-10-06

    原文格式PDF

  • 申请/专利权人 JACK ELIAS;

    申请/专利号US201113077473

  • 发明设计人 JACK ELIAS;

    申请日2011-03-31

  • 分类号A61K31/713;A61K31/56;A61K31/522;A61K31/7088;A61K31/739;A61P11;A61P31;A61P29;A61P25/04;A61P21/02;A61P35;

  • 国家 US

  • 入库时间 2022-08-21 18:11:14

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号